N/A N=59 Randomized Treatment

Behavioral Treatment of Adolescent Substance Use

Substance Use Disorders

Bottom Line

View on ClinicalTrials.gov: NCT02063984 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2021

Primary outcome: Primary: Any Cannabis Abstinence — 13; 18 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Intensive Outpatient Treatment (IOP) + Contingency Management (CM) (Behavioral); Working Memory Training (Behavioral)
Age: Pediatric, Adult · 12+ yrs
Sex: All
Sponsor: Dartmouth-Hitchcock Medical Center
Primary completion: Feb 2018

Outcome Measures

Outcome	Result	p-value
PRIMARY Any Cannabis Abstinence	13; 18	—
PRIMARY Weeks of Continuous Cannabis Abstinence	7.15; 4.88	—
SECONDARY Any Days of Cannabis Use	11; 14	—
SECONDARY Days of Cannabis Use	32.5; 24.5	—
SECONDARY Any Cannabis Abstinence Across Four Treatment Strategies	12; 12; 14; 11	—
SECONDARY Weeks of Cannabis Abstinence Across Four Treatment Strategies	6.17; 7.42; 5.29; 7.82	—

Summary

This study will continue research designed to improve treatment outcomes for adolescent substance use disorders by integrating neuroscience- and behaviorally-based treatments. In particular, this project will be the first to evaluate whether Working Memory Training can enhance cognitive function and reduce impulsive decision making to improve abstinence outcomes. In addition, an adaptive abstinence-based incentive program will be evaluated as a new method for intervening with those who do not respond to their first-line treatment.

Eligibility Criteria

Inclusion Criteria

Participants must be 12 to 26 years of age, must live at home with the parent who will participate, report using marijuana during the previous 30 days or provide a marijuana-positive urine test, meet criteria for cannabis abuse or dependence, and have a parent who can participate.

Exclusion Criteria: DSM criteria for dependence (likely to be adjusted for DSM-5 Use Disorder) on alcohol or other drugs other than marijuana (use of or meeting criteria for abuse of other substances will not be an exclusion criterion), active psychosis, severe medical or psychiatric illness limiting participation, or pregnant or breast-feeding.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02063984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.